TABLE 4.
Face-to-face
|
Videoconference
|
|||
---|---|---|---|---|
Success rate | 95% CI | Success rate | 95% CI | |
At follow-up (ITT) | n = 32 | n = 16 | ||
Reliable change | 55% | 40–69% | 56% | 37–74% |
Clinically significant change | 42% | 28–57% | 38% | 21–57% |
At posttreatment (ITT) | n = 23 | n = 12 | ||
Reliable change | 55% | 40–69% | 48% | 30–67% |
Clinically significant change | 47% | 33–61% | 33% | 18–53% |
At follow-up (AT) | n = 32 | n = 16 | ||
Reliable change | 74% | 54–87% | 87% | 57–97% |
Clinically significant change | 57% | 37–75% | 52% | 27–76% |
At posttreatment (AT) | n = 23 | n = 12 | ||
Reliable change | 73% | 55–85% | 71% | 47–88% |
Clinically significant change | 61% | 44–77% | 49% | 27–71% |